Utility of PD-L1 as a Biomarker in Bladder Cancer

Video

For High-Definition, Click

Promising data from a phase I trial exploring the anti-PD-L1 therapy MPDL3280A were presented at the 2014 ASCO Annual Meeting. In this study, the objective response rate with MPDL3280A was 43% in PD-L1 positive patients (IHC 2/3). At the time of the data cut-off, 94% of patients had ongoing responses.

At this point, the utility of PD-L1 as a biomarker of response seems unclear, explains Nicholas J. Vogelzang, MD. At this point, there currently does not appear to be a trend emerging from clinical trial data that PD-L1 is an effective biomarker of response for PD-1 and PD-L1 targeted immunotherapies. Despite these mixed signals, some companies are exploring companion diagnostics that look specifically at PD-L1 in conjunction with their immune checkpoint inhibitors, Vogelzang adds.

Tumor heterogeneity is the primary shortcoming of PD-L1 staining is patients with bladder cancer. Furthermore, Vogelzang notes, given the level of efficacy seen in PD-L1-negative tumors, it is difficult to make a life or death decision based upon an analysis of tissue from a biopsy that was taken two years old. As a result, at this point in the development of these novel therapies, Vogelzang remains unconvinced on the need for PD-L1 testing as a requirement for future clinical trials.

Related Videos
Arya Amini, MD
Adrianna Masters, MD, PhD,
Chul Kim, MD, MPH
Andrew Ip, MD
In this final episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, discuss a roadmap of artificial intelligence (AI) advances in the next 5 to 10 years.
In this eighth episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, explain how artificial intelligence tools are being developed to match the right patient to the right drug on the right clinical trial.
In this seventh episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, discuss how artificial intelligence tools may be utilized to improve wait time for treatment, to provide more time for provider-patient interactions, and more.
In this final episode of OncChats: Reviewing Best Practices in the Surgical Management of Breast Cancer, Gladys Giron, MD, FACS, and Cristina Lopez-Peñalver, MD, shed light on clinical outcomes following surgery of the primary tumor in patients with stage IV breast cancer.
In this sixth episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, discuss potential opportunities to leverage artificial intelligence tools in cancer screening, diagnosis, staging, and prognosis.
Christopher M. Gallagher, MD